Nxera Pharma Co.,Ltd. [4565.T]
TOKYO, Jun 10 (Pulse News Wire) – Nxera Pharma CO.,LTD. (4565.T) announced its participation in the OpenFold AI Research Consortium, alongside major pharmaceutical companies and tech firms such as Amazon Web Services, Microsoft, and NVIDIA.
The move aligns with the company’s strategy to enhance research and development productivity through AI technology, as presented at its annual shareholders' meeting on March 25, 2026. Through this collaboration, Nxera Pharma aims to accelerate drug discovery by integrating advanced computational chemistry and quantum computing approaches with structural biology analysis. The company's proprietary NxWave™ platform combines long-standing expertise in GPCR structure, unique data sets, and AI-driven methodologies to advance drug research.
Participation in OpenFold will enable Nxera Pharma to leverage cutting-edge open-source models and contribute to future research directions within the consortium. Patrick Folsch, CSO and President of Nxera Pharma UK, commented, “Joining the OpenFold consortium complements our design philosophy centered around the integration of structural biology, computational chemistry, and AI. It enhances our AI-driven drug discovery capabilities for challenging targets like GPCRs, supporting our broader strategic goals aimed at improving research efficiency and delivering differentiated molecules swiftly from target validation to clinical development.” While there will be no immediate impact on the fiscal year ending December 2026, the company expects this initiative to contribute positively to its long-term revenue growth and enterprise value.
🟢 Confidence: High AI-translated content.